Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. PaxMedica Inc. (PXMD) Message Board

Study Examines Role of African Sleeping Sickness i

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 90
(Total Views: 153)
Posted On: 11/17/2023 4:36:05 PM
Avatar
Posted By: NetworkNewsWire
Study Examines Role of African Sleeping Sickness in Body Wasting

African trypanosomiasis is a progressive illness that affects both humans and animals. The illness is caused by a parasite known as Trypanosoma brucei (T. brucei). In the course of infection, T. brucei colonizes adipose tissue and rapidly grows in the host. This, researchers theorize, may cause weight loss because it primarily affects the biggest visceral adipose tissue depot, the gonadal AT.

The infection works by offsetting the balance between anabolism and catabolism, which takes place in the adipocytes’ lipid droplets. An increase in lipid catabolism then causes degradation of triacylglycerol, which is hydrolyzed by lipase, monoacylglycerol lipase and adipose triglyceride lipase (ATGL) into diacylglycerol. Once this is done, free fatty acids and glycerol molecules are released into the interstitial spaces of adipose tissue and later, the circulatory system.

In a new study, researchers focused on finding evidence to support this theory, centering on the role free fatty acids played during infection. For their research, the scientists infected mice with T. brucei then conducted histological analyses after collecting gonadal AT at different stages postinfection. They also treated chemically sympathectomizing mice with a dopamine analog dubbed 6-OHDA, to prevent the release of norepinephrine from sympathetic neurons. This allowed them to explore whether sympathetic innervation contributed to fat loss induced by the T. brucei parasite.

In addition to this, the mice were subjected to periods of fasting, followed by paired-feeding or refeeding. The researchers observed higher adipocyte lipolysis in the infected mice in comparison with the controls, which indicates that hypophagia induced by the T. brucei infection didn’t cause adipocyte lipolysis.

The researchers also observed progressive weight loss in T-brucei-infected mice, recording 30%, 54% and 65% loss in weight on days 10, 16 and 30 postinfection. This was in addition to observing reductions in adipocyte lipid droplet area, which fell by 44%, 54% and 65% respectively on the aforementioned days.

The researchers then stimulated adipose tissue explants with a lipolysis inducer, forskolin, but saw no release of lipolytic products. This, they noted, indicated that T. brucei caused adipose tissue atrophy that couldn’t be reversed to levels seen prior to the infection. In their report, the researchers stated that they observed reductions in interstitial concentrations of free fatty acids on days 9, 16 and 30 following infection.

In their conclusion, the researchers explained that adipocyte shrinkage seemed to be dependent on ATGL lipolysis. They also noted that while other lipid-based pathways could play a role in fat wasting during infection, ATGL was a crucial aspect of adipocyte lipolysis. In addition, they highlighted the need for future research to focus on better understanding glycerol’s role during T. brucei infection.

The study’s findings were reported in “Nature Microbiology.”

Entities such as PaxMedica Inc. (NASDAQ: PXMD) are working to develop effective treatments against African sleeping sickness. This could in turn address complications such as the body wasting experienced by people who have ever suffered from this infection.

NOTE TO INVESTORS: The latest news and updates relating to PaxMedica Inc. (NASDAQ: PXMD) are available in the company’s newsroom at https://ibn.fm/PXMD

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer




(0)
(0)




PaxMedica Inc. (PXMD) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us